Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655342 | 1.00 | MAPK1 (0.65) | MAPK1SMN1; SMN2RAB9ACNR1MEN1 | |
| SCHEMBL2755853 | 0.87 | MAPK1 (0.60) | MAPK1SMN1; SMN2RAB9ACNR1MEN1 | |
| SCHEMBL30206599 | 0.87 | MAPK1 (0.60) | MAPK1SMN1; SMN2RAB9ACNR1MEN1 | |
| SCHEMBL31558918 | 0.83 | SMN1; SMN2 (0.80) | SMN1; SMN2RAB9AMEN1NPC1KMT2A | |
| SCHEMBL16866627 | 0.83 | MAPK1 (0.64) | MAPK1SMN1; SMN2RAB9ACNR1MEN1 | |
| SCHEMBL1694984 | 0.81 | RAB9A (0.62) | MAPK1SMN1; SMN2RAB9ACNR1MEN1 | |
| SCHEMBL27263888 | 0.81 | RAB9A (0.58) | MAPK1SMN1; SMN2RAB9ACNR1MEN1 | |
| SCHEMBL702021 | 0.80 | TAS1R3 (0.58) | MAPK1SMN1; SMN2RAB9AMEN1NPC1 | |
| SCHEMBL10192960 | 0.80 | SMN1; SMN2 (0.65) | MAPK1SMN1; SMN2RAB9ACNR1NPC1 | |
| SCHEMBL170486 | 0.80 | RAB9A (0.57) | MAPK1SMN1; SMN2RAB9ACNR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673085-A4 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-12-10 | — | — | EP | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | claimed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | claimed |
| US-20220326230-A1 | NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF | FIRMENICH INCORPORATED (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3235811-B1 | PROCESS OF PREPARING OXALAMIDES | SENOMYX INC (US) | 2018-07-25 | — | — | EP | disclosed |
| CN-101400336-B | Novel flavoring agents, taste modifiers, tastants, taste enhancers, umami or sweeteners and/or enhancers and uses thereof | SENOMYX INC | 2013-06-05 | — | — | CN | disclosed |
| CN-101400336-A | Novel flavoring agents, taste modifiers, tastants, taste enhancers, umami or sweeteners and/or enhancers and uses thereof | SENOMYX INC (US) | 2009-04-01 | — | — | CN | disclosed |
| EP-1673085-A4 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-12-10 | — | — | EP | disclosed |
| CN-101203142-A | Aromatic amides and ureas and their uses as sweet and/or delicate flavor modifiers, flavouring agents and taste enhancers | SENOMYX INC (US) | 2008-06-18 | — | — | CN | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220326230-A1 | NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF | TAS1R2, TAS1R1, TAS2R30 | MAPK1 2085/4885SMN1; SMN2 2560/4885RAB9A 4173/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | MAPK1 19/4885SMN1; SMN2 3846/4885RAB9A 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.